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ditorialtate  of  the  art  science  addressing  injecting  drug  use,  HIV  and  harm
eductionUnsafe injecting drug use continues to drive the HIV epidemics
n many countries around the world. The United Nations Ofﬁce on
rugs and Crime (UNODC), Joint United Nations Programme on
IDS (UNAIDS), World Health Organization (WHO) and the World
ank estimate that there are 12.7 million (range: 8.9–22.4 mil-
ion) people who inject drugs (PWID), globally. Among them, 13.1
er cent or 1.7 million people (range: 0.9–4.8 million) are living
ith HIV, with wide variations between regions and countries.
he HIV situation is of particular concern in South-West Asia and
n Eastern and South-Eastern Europe and Central Asia, where the
revalence of HIV among PWID is estimated to be between 23
nd 29 percent, respectively. While HIV in sub-Saharan Africa is
ransmitted mainly via unprotected sexual intercourse, HIV trans-
ission through unsafe injecting drug use has now also emerged
s a signiﬁcant concern in East Africa, and has also been reported
n several countries in other parts of Africa (UNODC, 2014). In
ddition, high risk sexual practices linked to the use of stimu-
ant drugs (e.g. amphetamine-type stimulants, cocaine) among key
opulations – for example, men  having sex with men  – are also
ontributing to the spread of HIV in certain parts of the world.
To respond to HIV and associated epidemics among people who
nject drugs, WHO, UNODC and UNAIDS have jointly recommended
 package of nine interventions, commonly referred to as a ‘harm
eduction’ approach to injecting drug use (WHO, UNODC & UNAIDS
012), aimed at reducing the risk of acquiring and improving treat-
ent and care of HIV, hepatitis and TB in PWID. The ﬁrst four
nterventions: needle-syringe programmes (NSP), opioid substitu-
ion therapy (OST), testing and counseling for HIV and provision
f antiretroviral therapy (ART) are the most critical. There is com-
elling evidence that NSP and OST are effective in reducing the
haring of injecting equipment and averting HIV infections. In com-
ination with ART, these interventions reduce HIV transmission,
ecrease mortality, reduce drug dependency, and improve quality
f life.
In March 2014, UNODC organized, in the context of the High-
evel Review of the 57th session of CND, a one-day Scientiﬁc
onsultation in Vienna, entitled “Science addressing drugs and HIV:
tate of the Art”, where it brought together leading scientists to dis-
uss the latest developments in prevention and treatment of HIV
nd AIDS as it relates to drug use. The presentations and discussions
t the Scientiﬁc Consultation revolved around six thematic top-
cs, pre-identiﬁed by UNODC, in consultation with its civil society
artners. These were: The cost effectiveness of harm reduction; HIV,
ttp://dx.doi.org/10.1016/j.drugpo.2014.11.008
955-3959/© 2015 The Authors. Published by Elsevier B.V. This is an open access article undrugs and the legal environment; Women and drugs; Harm reduction
in prisons; Compulsory detention as drug treatment and the impact
on HIV outcomes; and Prevention, treatment and care of hepatitis
C among people who inject drugs. The scientists were encouraged
to reach out to a broader group of the relevant scientiﬁc com-
munity and gather its inputs as they were to prepare for their
individual thematic paper and related presentation at the Scientiﬁc
Consultation.In their commentary, Wilson, Braedon, Shattock, and
Fraser-Hurt (2015) demonstrate the cost-effectiveness of key harm
reduction interventions for people who  inject drugs, from both gov-
ernment and societal perspectives, in terms of HIV outcomes and
drug dependency. The commentary also provides a brief overview
of current implementation levels of the various interventions by
region. Access to comprehensive harm reduction services for PWID
remains disproportionately low. As of 2010, globally, fewer than 8
in 100 PWID have access to OST, only 2 sterile needles are dis-
tributed per month per PWID and only 4 in every 100 eligible
people who inject drugs are receiving ART (Mathers et al., 2010).
HIV services are typically not responsive to the speciﬁc needs of
particularly vulnerable groups of PWID, in particular women, young
people, and those living in prisons and other closed settings. In the
commentary by Azim, Bontell, and Strathdee (2015) the authors
discuss the reasons why women who use drugs are particularly vul-
nerable to HIV infection, suggesting that interventions to optimize
HIV prevention and care need to be sensitive to the needs of women
and often, their children.A growing body of evidence indicates that
the main factors behind the disproportionately low access to harm
reduction services among PWID include: the lack of supporting
drug policies and legislation in many countries; over-reliance of
many national drug control systems on sanctions and over-use
of incarceration of people who use drugs; compulsory detention
for drug use and punitive practices in a number of countries in
the name of treatment for drug dependence; and stigma and dis-
crimination. In their commentary, Strathdee, Beletsky, and Kerr
(2015) show how the legal environment, such as policing prac-
tices, are directly or indirectly responsible for elevated HIV risks
among PWID. They also present examples where police educa-
tion programs and supportive policing practices can enhance harm
reduction programs rather than undermining them. The commen-
tary by Kamarulzaman and Mc  Brayer (2015) provide an overview
on the increased international attention and the evolving response
to the human rights abuses and the denial of medical care that often
exist within the compulsory drug detention centres. It also high-
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ights an increased risk of HIV transmission within these centres,
roviding further evidence calling for their closure.
The commentary by Dolan et al. (2015) reports that PWID
re over-represented among prison populations, among whom
IV prevalence is elevated (Dolan et al., 2015). Since HIV pre-
ention, including NSP and OST is provided very rarely in these
ettings, advocacy is needed to shift the focus of prison policies
owards implementation of harm reduction programs, including
rug dependence treatment, to protect the health of inmates and
he general public.
Beyond HIV, Hepatitis C and TB epidemics are also tightly inter-
inked with injecting drug use and signiﬁcant proportions of PWID
re co-infected with two or three of these infections. The commen-
ary by Bruggmann and Grebely (2015) reports that despite the fact
hat two-thirds of PWID are estimated to be living with hepatitis C
irus (HCV), awareness of HCV is generally low, even among health
roviders, and access to HCV testing and treatment is very poor.
Based on the six thematic papers and the follow up discuss-
ons among the lead authors during the Scientiﬁc Consultation,
 Scientiﬁc Statement was produced which was presented at the
lenary of the High-level Review of the CND. The text of this
cientiﬁc Statement follows this editorial. The individual scien-
iﬁc contributions to the pre-CND consultation have now been
e-drafted, peer-reviewed and are assembled, together with the
cientiﬁc Statement in this special issue of the International Jour-
al of Drug Policy.  We  are grateful to the authors and to the
ditors of the Journal for making this special issue of the IJDP
ossible.
onﬂict of interest statement
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 scientiﬁc  statement
ontext
As the Commission on Narcotic Drugs (CND) conducts its high-
evel review of the implementation of the Political Declaration and
lan of Action, there remains a signiﬁcant discrepancy between
hat science has shown actually works,  and what in reality is being
mplemented in countries most affected by HIV and hepatitis C epi-
emics driven by unsafe injecting drug use.
It is estimated that, of the estimated 13 (9–22) million
eople who inject drugs worldwide, 13% are living with HIV
nd more than 60% live with the hepatitis C virus with large
egional variation. As long as effective measures to reduce
rug consumption and unsafe injection are not implemented,
IV and hepatitis C virus will continue to spread among peo-
le who inject drugs and ultimately to their partners and to
in Eastern Europe and central Asia and throughout the rest of the
Asian region.
In its resolution 56/6 in 2013, the Commission on Narcotic Drugs
requested United Nations Ofﬁce on Drugs and Crime (UNODC) to
implement, as appropriate, the joint WHO, UNODC and UNAIDS-
recommended comprehensive package of services for people
who inject drugs, also known as harm reduction services, which
includes: (a) Needle and syringe programs (NSP) that provide
people who inject drugs with sterile injecting equipment and
remove contaminated injection material from circulation; (b) Opi-
oid substitution therapy (OST), and other evidence-based drug
dependence treatment. Opioid substitution therapy is the best
researched and most effective form of treatment of opioid depend-
ence; it is also highly effective to prevent HIV among people
who inject drugs; (c) HIV testing and counseling; (d) Antiretro-ociety in general. The HIV/AIDS and hepatitis C epidemics as
hese relate to injecting drug use are of particular concernviral therapy (ART). Antiretroviral therapy is effective for people
who inject drugs as for other patients when associated with
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ppropriate support; (e) Prevention and treatment of sexually
ransmitted infections; (f) Condom programs for people who inject
rugs and their sexual partners; (g) Targeted information, edu-
ation and communication for people who inject drugs and their
exual partners; (h) Prevention, vaccination, diagnosis and treat-
ent for viral hepatitis; (i) Prevention, diagnosis and treatment of
uberculosis.
Recent studies indicate that that the combination of opioid sub-
titution therapy and needle and syringe programs can signiﬁcantly
educe injecting risk behavior, HIV and, to a lower degree, hepati-
is C incidence. Needle and syringe programs, opioid substitution
herapy and antiretroviral therapy have a synergistic impact on the
eduction of HIV incidence at a population level.
The absence of an enabling legal and policy environment and
upporting regulatory framework, continues to hamper effective
mplementation of these programs. In many countries of the world,
he provision of these evidence-based UN-recommended HIV inter-
entions for people who inject drugs remains very limited or even
bsent.
According to the Harm Reduction International’s Global State
f Harm Reduction latest report, 97 countries and territories cur-
ently support a harm reduction approach, this support being
xplicit either in national policy documents in eighty-three
ountries, and/or through the implementation or tolerance of
arm reduction interventions such as needle and syringe pro-
rams in eighty-six countries, or opioid substitution therapy in
eventy-seven countries. Expansion of harm reduction programs
as been slow and many of the new programs remain small-
cale pilots. Based on the same report, opioid substitution therapy
n prisons was available in only forty-one countries and nee-
le and syringe programs in prisons in only ten countries. In
ost low- and middle-income countries coverage of harm reduc-
ion services remains by far insufﬁcient to stabilize and reverse
IV and viral hepatitis epidemics among people who  inject
rugs.
cientiﬁc statement
The following statement represents the current scientiﬁc evi-
ence on prevention and treatment of HIV and hepatitis as it relates
o injecting drug use.
. There is unambiguous and compelling evidence that shar-
ing of injecting equipment is strongly associated with the
risk of acquiring HIV and hepatitis C and its ongoing spread.
Criminalization of drug use, restrictive drug policies and
aggressive law enforcement practices are key drivers of
HIV and hepatitis C epidemics among people who inject
drugs. Drug policies should fully integrate and prioritize
both public and individual health in order to implement
strategic and effective responses to improve health among
people who inject drugs, their communities and the general
population.
. There is compelling evidence that needle and syringe programs
(NSP) and opioid substitution therapy (OST) are effective in
reducing sharing of injecting equipment and averting HIV infec-
tions. Together with antiretroviral therapy (ART), which is also
highly likely to reduce HIV transmission among people who
inject drugs, needle and syringe programs and opioid substi-
tution therapy improve quality of life, decrease mortality and
reduce drug dependency. There is also evidence that these
harm reduction interventions reduce crime and public disor-
der, improve social functioning and provide a bridge to drug
dependence treatment.rug Policy 26 (2015) S1–S4 S3
Harm reduction interventions are good value for money. There
is compelling evidence of cost-effectiveness for each of the three
interventions across all regions of the world, with average costs
per HIV infection averted ranging from $100 to $1000.
The coverage of harm reduction programs is currently too low
across almost all regions to have impact on spread of new HIV
and hepatitis C infections. Scaling up harm reduction programs is
a worthwhile investment; not only do the community beneﬁts of
harm reduction programs exceed treatment costs, but they also
have the potential to provide signiﬁcant returns on investments
for governments.
The large number of people who inject drugs who are incarcer-
ated and the high HIV and hepatitis C prevalence among them,
together with the absence of effective harm reduction services in
prisons, hamper efforts to reduce HIV prevalence among people
who inject drugs and in the community. We need to stop incar-
ceration of people who use drugs for minor drug related offenses,
including by referral to HIV and drug services in the community.
Laws and policies should be implemented to ensure that the
rights of people in prisons and pre-trial detention, including
people who  inject drugs, to access equivalent health care are
respected.
Compulsory centers for drug users (CCDUs) currently oper-
ate in many countries. These centres are not only ineffective
in reducing drug use but often times represent acts of abuse
and torture. HIV prevention and treatment is not provided
in these centers where a high proportion of the detainees is
either HIV positive or are at very high risk for infection. The
United Nations has repeatedly called for the closure of these
centres.
Women  who  inject drugs often have higher rates of HIV than
their male counterparts. Women  who use drugs and sell sex are
even more vulnerable to HIV. Harm reduction should be included
in all interventions for sex workers and safer sex messages
should be part of all harm reduction programs for women  who
inject drugs. Reproductive health services should be integrated
with harm reduction services. Women  who are sex partners of
men  who inject drugs but do not inject drugs themselves are vul-
nerable to HIV infection because of low condom use and intimate
partner violence.
3. Laws and policies that undermine access to harm reduction are
key drivers of HIV and hepatitis C risks among people who inject
drugs. Laws that criminalize drug use and possession result in
stigma and policy displacement, which in turn undermine sup-
port for harm reduction. In addition, law enforcement practices
and especially unauthorized policing practices are a pervasive
barrier to the implementation and effectiveness of harm reduc-
tion programs.
Laws facilitating needle and syringe programs and opioid
substitution therapy are effective “structural” interventions to
curb HIV and hepatitis C virus spread among people who inject
drugs. There is an urgent need to re-align harm reduction
and law enforcement approaches to support prevention and
treatment of HIV and hepatitis C among people who inject
drugs.
4. Hepatitis C is a rising cause of severe liver disease and pre-
mature death among people who inject drugs, and represents
a growing public health, social and economic burden. Aware-
ness of the hepatitis C infection among people who  inject
drugs is low although the infection is highly prevalent in
this population. Hepatitis C virus testing is rarely available
to people who inject drugs worldwide, and even less have
access to treatment, despite the evidence that the infection
is curable. Successful hepatitis C prevention strategies com-
bine high coverage of harm reduction measures with hepatitis
C treatment.
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There is an urgent need to integrate hepatitis C treat-
ment services into harm reduction services to enhance
treatment uptake and cure rates. Novel, well-tolerated, and
efﬁcacious hepatitis C treatment regimens now offer the oppor-
tunity to treat the majority of infected people who inject
drugs.
This scientiﬁc statement was produced in the context of a
scientiﬁc consultation entitled “Science addressing drugs and
Health: State of the Art” organized by the United Nations Ofﬁce
Adeeba Kamarulzaman, Philip Bruggmann, and their respective
co-authors, under the overall guidance of the Co-Chair of the sci-
entiﬁc consultation Michel Kazatchkine, United Nations Secretaryon Drugs and Crime (UNODC) on 11 March 2014, preceding the
high-level segment of the 57th session of the Commission on
Narcotic Drugs (CND) based on thematic papers developed by
David Wilson, Steffanie Strathdee, Tasnim Azim, Kate Dolan,General’s Special Envoy on HIV/AIDS for Eastern Europe and Cen-
tral Asia and Monica Beg, Riku Lehtovuori and Fabienne Hariga of
UNODC.
